Form D · Biotechnology
Myrobalan Therapeutics Holding, Inc.
Medford, MA · CIK 0002009058
Offering snapshot reported Jan 24, 2024 · SEC filing
- Reported sold
- $24M Offering amount: $24M
- Investors reported
- 12 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 9, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 24, 2024 | Initial | $24,049,258 | No comparison | 12 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-503241
Amount sold includes securities that converted.
Source: Form D, filed Jan 24, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Guoping Feng | Director |
| Zhigang He | Director |
| Jing Yu Wang | Director, Executive |
| Shixiang Yan | Director |
| Minmin Yang | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
200 Boston Avenue, Suite G750
Medford, MA, 02155
Medford, MA, 02155